Bristol Myers Squibb stock gains after trial success

Published on 09/08/2026 at 20:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock is in focus after Reuters said on September 8, 2026 that its blood cancer cell therapy met the main goal in a mid-stage trial.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US1078421011) traded at USD 66.82 after Reuters said on September 8, 2026 that the group's experimental blood cancer cell therapy met the main goal in a mid-stage trial.Reuters The same-day backdrop also included a prior close of USD 66.78 on September 5, 2026 and a move of minus 1.9 percent, which kept the stock near the USD 66.85 level seen on September 7, 2026.

Trial data now matter

The catalyst is the QUINTESSENTIAL study of arlocabtagene autoleucel, a Phase 2 program that Bristol Myers Squibb described in its own release on September 8, 2026 as producing positive topline results in relapsed and refractory multiple myeloma.Bristol Myers Squibb That makes the program more than a pipeline headline: the company is trying to turn a cell therapy readout into a clearer commercial asset.

MarketBeat's September 8, 2026 coverage said Bristol Myers Squibb reported quarterly EPS of USD 2.04 versus the USD 1.60 consensus, while revenue reached USD 12.97 billion against USD 11.74 billion expected.MarketBeat The same report said fiscal 2026 EPS guidance remains at USD 6.75 to USD 7.00, giving investors a fresh reference point for the valuation debate.

Guidance and valuation

The numbers show the setup: revenue rose 5.7 percent year over year, EPS beat consensus by USD 0.44, and the stock was quoted around USD 66.82 to USD 66.85 on September 7 and September 8, 2026. That combination links the clinical news to a business already delivering above-consensus earnings power.

GuruFocus said on September 8, 2026 that Bristol Myers Squibb carried a market capitalization of USD 136.49 billion and traded at USD 66.82, which it placed about 18.2 percent above its GF Value of USD 56.54.GuruFocus The same data point also implied a trailing P/E of 14.72 times, below the 5-year median of 18.13 times.

Dividend stays relevant

Bristol Myers Squibb also still leans on cash returns. Yahoo Finance-linked coverage on September 8, 2026 said the company traded at USD 66.83 and paid a quarterly dividend of USD 0.63, or USD 2.52 annualized, after a 17th straight annual dividend increase.Yahoo Finance That dividend profile helps explain why the stock can hold investor attention even when the next step depends on trial execution.

Price level and setup

Bristol Myers Squibb stock ended the latest quoted session near USD 66.82 to USD 66.85 on the NYSE, with the market cap at USD 136.49 billion on September 8, 2026. For the next trading screen, the key question is whether the trial readout can sustain that valuation band.